Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Gains from Investment Securities (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Gains from Investment Securities data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, changed N/A, while the annual FY2024 figure was $3865.0, 399.35% up from the prior year.
  • Gains from Investment Securities reached $1.2 million in Q3 2025 per TNXP's latest filing, roughly flat from $1.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.2 million in Q1 2023 and bottomed at $774.0 in Q4 2023.
  • Average Gains from Investment Securities over 3 years is $1.4 million, with a median of $762645.5 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: crashed 98.75% in 2024, then soared 548.63% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at $774.0 in 2023, then soared by 399.35% to $3865.0 in 2024, then skyrocketed by 29857.08% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $1.2 million in Q3 2025, $1.2 million in Q2 2025, and $670291.0 in Q1 2025.